KLAS
4.6.2024 11:01:28 CEST | Business Wire | Press release
Klas, a global leader in rugged edge technology solutions, is proud to unveil its most advanced vehicle data logging solution yet - the TRX D16. This cutting-edge device combines high-performance computing (HPC) and storage into a single platform, revolutionizing ADAS/AD development and data logging for both lab and in-vehicle use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604506618/en/
TRX D16 from Klas - HPC ADAS/AD Development Server & Cloud Scale Data Logging (Photo: Business Wire)
The TRX D16 introduces transformational advancements to in-vehicle computing and logging and unleashes technology confined to the cloud or extremely large loggers up to this point. Now, high-end computing and logging can be fitted to any vehicle platform, allowing engineers to continue pushing the limits of ADAS/AD.
With TRX D16, automotive engineers gain a high-performance and customizable platform to accommodate the evolving vehicle sensor stack and support compute-intensive software development of AI/ML training, inference, and simulation. Furthermore, the platform delivers 200Gbps of sustained logging speeds and 480TB of data storage to capture data from high-speed ethernet-based cameras, with support for denser radar and lidar point cloud captures.
Designed rugged, the TRX D16 is equally at home in the lab and the vehicle. Engineers can transfer the entire development environment workbench to the vehicle for continued development and integration of new functionality with real-world drive test scenarios.
“As a single platform, the multi-purpose TRX D16 minimizes the number of disparate systems in the vehicle and reduces the effort of moving from the lab to the vehicle,” said Frank Murray, CTO of Klas. “By reducing the time spent preparing the vehicle, engineers can focus on productive tasks of real-world validation, which includes high-performance computing for AI testing. At a program level, the result is the improved time to market for new ADAS/AD functionality.”
TRX D16 key features
The TRX D16 is designed rugged to the highest specifications of MIL-STD-461 and 810G/H to withstand the extremes of temperature, vibration and shock.
- High performance computing: AMD EPYC™ 7713P (64 core) processor and up to 768GB of RAM, designed for embedded and harsh environments in vehicles.
- Open GPU options: Numerous GPU PCIe card options are supported, allowing for more flexible and cost-effective AI/ML development environments.
- Hot-swappable storage: 480 TB storage (16x SSDs) split over two removable cassettes allows test vehicles to return to the road in minutes with minimal IT effort.
- High disk write speeds: SAS4 SED drives, plus integrated RAID for secure data capture from an increased number of high-bandwidth sensors.
- High speed connectivity: 2x 100GbE interfaces to transfer valuable data to engineering HIL/SIL workbenches.
- Flexible expansion: 2x PCIe (Gen 4) interfaces for custom I/O - automotive Ethernet, FPGA based SmartNICs, GMSL/FPD-Link/GVIF based cameras, or storage.
To learn more about the TRX D16 HPC server and vehicle data logger or Klas, visit -
https://www.klasgroup.com/markets/automotive/l4-l5-data-logging/
About Klas
Klas is an engineering and design company with over 30 years of experience developing innovative rugged communications solutions for the network edge. The company specializes in integrating enterprise networking capabilities from global IT leaders with purpose-built hardware and software platforms designed to meet market demands and the most stringent environmental requirements. Klas collaborates with strategic partners, including Cisco, Dell, and Microsoft, to support edge deployments in Government, Transportation, and Automotive industries. For more information, visit www.klasgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604506618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom